Ying C Henderson1, Soon-Hyun Ahn, Gary L Clayman. 1. Department of Head and Neck Surgery, The University of Texas, M.D. Anderson Cancer Center, 1515 Holcombe Blvd, Unit 441, Houston, TX 77030, USA.
Abstract
BACKGROUND: Papillary thyroid carcinoma (PTC), the most common type of thyroid malignancy, usually possesses mutations, either RET/PTC rearrangement or BRAF mutation. Both mutations can activate the mitogen-activated protein kinase kinase/extracellular signal-related kinase signaling transduction pathway, which results in activation of transcription factors that regulate cellular proliferation, differentiation, and apoptosis. OBJECTIVE: To test the effects of CI-1040 (PD184352), a specific MEK1/2 inhibitor, on PTC cells carrying either an RET/PTC1 rearrangement or a BRAF mutation. DESIGN: The effects of CI-1040 on PTC cells were evaluated in vitro and in vivo. MAIN OUTCOME MEASURES: The effects of CI-1040 on PTC cells were evaluated in vitro using a cell proliferation assay, cell cycle analysis, and immunoblotting. The antitumor effects of CI-1040 in vivo were evaluated in an orthotopic mouse model. RESULTS: The concentrations of CI-1040 needed to inhibit 50% cell growth were 0.052microM for PTC cells with a BRAF mutation and 1.1microM for PTC cells with the RET/PTC1 rearrangement. After 3 weeks of oral administration of CI-1040 (300 mg/kg/d) to mice with orthotopic tumor implants of PTC cells, the mean tumor volume of implants bearing the RET/PTC1 rearrangement (n = 5) was reduced 47.5% compared with untreated mice (from 701.9 to 368.5 mm(3)), and the mean volume of implants with a BRAF mutation (n = 8) was reduced 31.3% (from 297.3 to 204.2 mm(3)). CONCLUSIONS: CI-1040 inhibits PTC cell growth in vitro and in vivo. Because RET/PTC rearrangements are unique to thyroid carcinomas and a high percentage of PTCs possess either mutation, these findings support the clinical evaluation of CI-1040 for patients with PTC.
BACKGROUND:Papillary thyroid carcinoma (PTC), the most common type of thyroid malignancy, usually possesses mutations, either RET/PTC rearrangement or BRAF mutation. Both mutations can activate the mitogen-activated protein kinase kinase/extracellular signal-related kinase signaling transduction pathway, which results in activation of transcription factors that regulate cellular proliferation, differentiation, and apoptosis. OBJECTIVE: To test the effects of CI-1040 (PD184352), a specific MEK1/2 inhibitor, on PTC cells carrying either an RET/PTC1 rearrangement or a BRAF mutation. DESIGN: The effects of CI-1040 on PTC cells were evaluated in vitro and in vivo. MAIN OUTCOME MEASURES: The effects of CI-1040 on PTC cells were evaluated in vitro using a cell proliferation assay, cell cycle analysis, and immunoblotting. The antitumor effects of CI-1040 in vivo were evaluated in an orthotopic mouse model. RESULTS: The concentrations of CI-1040 needed to inhibit 50% cell growth were 0.052microM for PTC cells with a BRAF mutation and 1.1microM for PTC cells with the RET/PTC1 rearrangement. After 3 weeks of oral administration of CI-1040 (300 mg/kg/d) to mice with orthotopic tumor implants of PTC cells, the mean tumor volume of implants bearing the RET/PTC1 rearrangement (n = 5) was reduced 47.5% compared with untreated mice (from 701.9 to 368.5 mm(3)), and the mean volume of implants with a BRAF mutation (n = 8) was reduced 31.3% (from 297.3 to 204.2 mm(3)). CONCLUSIONS:CI-1040 inhibits PTC cell growth in vitro and in vivo. Because RET/PTC rearrangements are unique to thyroid carcinomas and a high percentage of PTCs possess either mutation, these findings support the clinical evaluation of CI-1040 for patients with PTC.
Authors: John Rinehart; Alex A Adjei; Patricia M Lorusso; David Waterhouse; J Randolph Hecht; Ronald B Natale; Oday Hamid; Mary Varterasian; Peggy Asbury; Eric P Kaldjian; Stephen Gulyas; David Y Mitchell; Roman Herrera; Judith S Sebolt-Leopold; Mark B Meyer Journal: J Clin Oncol Date: 2004-10-13 Impact factor: 44.544
Authors: Patrick J Klein; C Max Schmidt; Chad A Wiesenauer; Jennifer N Choi; Earl A Gage; Michele T Yip-Schneider; Eric A Wiebke; Yufang Wang; Charles Omer; Judith S Sebolt-Leopold Journal: Neoplasia Date: 2006-01 Impact factor: 5.715
Authors: Helen Davies; Graham R Bignell; Charles Cox; Philip Stephens; Sarah Edkins; Sheila Clegg; Jon Teague; Hayley Woffendin; Mathew J Garnett; William Bottomley; Neil Davis; Ed Dicks; Rebecca Ewing; Yvonne Floyd; Kristian Gray; Sarah Hall; Rachel Hawes; Jaime Hughes; Vivian Kosmidou; Andrew Menzies; Catherine Mould; Adrian Parker; Claire Stevens; Stephen Watt; Steven Hooper; Rebecca Wilson; Hiran Jayatilake; Barry A Gusterson; Colin Cooper; Janet Shipley; Darren Hargrave; Katherine Pritchard-Jones; Norman Maitland; Georgia Chenevix-Trench; Gregory J Riggins; Darell D Bigner; Giuseppe Palmieri; Antonio Cossu; Adrienne Flanagan; Andrew Nicholson; Judy W C Ho; Suet Y Leung; Siu T Yuen; Barbara L Weber; Hilliard F Seigler; Timothy L Darrow; Hugh Paterson; Richard Marais; Christopher J Marshall; Richard Wooster; Michael R Stratton; P Andrew Futreal Journal: Nature Date: 2002-06-09 Impact factor: 49.962
Authors: Ying C Henderson; Yunyun Chen; Mitchell J Frederick; Stephen Y Lai; Gary L Clayman Journal: Mol Cancer Ther Date: 2010-06-29 Impact factor: 6.261
Authors: Jennifer A Morrison; Laura A Pike; Greg Lund; Qiong Zhou; Brittelle E Kessler; Kevin T Bauerle; Sharon B Sams; Bryan R Haugen; Rebecca E Schweppe Journal: Horm Cancer Date: 2015-03-24 Impact factor: 3.869
Authors: Randall W Alfano; Stephen H Leppla; Shihui Liu; Thomas H Bugge; Janelle M Ortiz; Terry C Lairmore; Nicholas S Duesbery; Ian C Mitchell; Fiemu Nwariaku; Arthur E Frankel Journal: Mol Cancer Ther Date: 2010-01-06 Impact factor: 6.261
Authors: Ying C Henderson; Rafael Toro-Serra; Yunyun Chen; Junsun Ryu; Mitchell J Frederick; Ge Zhou; Gary E Gallick; Stephen Y Lai; Gary L Clayman Journal: Head Neck Date: 2013-06-01 Impact factor: 3.147